Mode
Text Size
Log in / Sign up

Systemic juvenile idiopathic arthritis

Part of Arthritis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Systemic juvenile idiopathic arthritis

3 trials tracked for Systemic juvenile idiopathic arthritis: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 129 citations.

3Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3
  1. Phase 3 An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. Completed · 129 cited
  2. Phase 3 Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA Completed · 21 cited
  3. Phase 3 A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Arthritis

Related studies from across the Arthritis family.

ACR20 overestimates treatment effects compared to target-based outcomes in patients with rheumatoid arthritis
Rheumatology Meta-analysis
ACR20 overestimates treatment effects compared to target-based outcomes in patients with rheumatoid arthritis New data shows specific goals better track rheumatoid arthritis success
This meta-epidemiological study of 30,778 patients with rheumatoid arthritis evaluates the concordance between ACR response criteria and tar…
New research shows that some common ways of measuring rheumatoid arthritis progress may overestimate how well a treatment is actually workin…
Exercise improves physical function and reduces pain in adults with rheumatoid arthritis
Rheumatology Meta-analysis
Exercise improves physical function and reduces pain in adults with rheumatoid arthritis Exercise Shows Small Gains for Rheumatoid Arthritis
This meta-analysis of 20 studies involving 1487 participants for physical function and 14 studies involving 998 participants for pain indica…
Exercise may slightly improve physical function and pain in rheumatoid arthritis, but more research is needed.
CDAI and SDAI scores improve prediction of osteoporosis in patients with rheumatoid arthritis
Rheumatology Guideline
CDAI and SDAI scores improve prediction of osteoporosis in patients with rheumatoid arthritis New scores help identify osteoporosis risk in rheumatoid arthritis patients
This guideline provides a cross-sectional analysis of osteoporosis prediction in patients with rheumatoid arthritis. The authors found that …
Specific disease-activity scores can help doctors better identify osteoporosis risk in patients living with rheumatoid arthritis.
Caulophyllum robustum extracts show anti-inflammatory and bone protective activity in preclinical models of rheumatoid arthritis
Drug Pipeline Sys. Review
Caulophyllum robustum extracts show anti-inflammatory and bone protective activity in preclinical models of rheumatoid arthritis Caulophyllum robustum Shows Potential Activity Against Rheumatoid Arthritis
This systematic review synthesizes preclinical evidence regarding Caulophyllum robustum components, including triterpenoid saponins and alka…
Early laboratory research suggests that compounds found in Caulophyllum robustum may help manage inflammation and joint damage in rheumatoid…
Adalimumab significantly improves ACR70 and PASI100 outcomes in patients with psoriatic arthritis
Dermatology Meta-analysis
Adalimumab significantly improves ACR70 and PASI100 outcomes in patients with psoriatic arthritis Trial data shows adalimumab helps manage psoriatic arthritis symptoms
This meta-analysis of 5,655 patients with psoriatic arthritis found that adalimumab significantly improved multiple clinical markers includi…
New analysis of over 5,000 patients shows the drug adalimumab significantly improves skin and joint symptoms for those with psoriatic arthri…
Engineered nanobodies offer programmable platform to overcome limitations of conventional antibodies in angiogenic diseases
Allergy & Immunology Sys. Review
Engineered nanobodies offer programmable platform to overcome limitations of conventional antibodies in angiogenic diseases Engineered nanobodies may offer better ways to treat solid tumors
This systematic review examines engineered nanobodies targeting angiogenesis-related pathways for solid tumors and other conditions like wet…
Tiny engineered proteins called nanobodies could overcome the limitations of standard treatments for solid tumors and other blood vessel-rel…
Tailor-made DMARD selection based on autoantibody status does not improve DAS scores in RA
Rheumatology RCT
Tailor-made DMARD selection based on autoantibody status does not improve DAS scores in RA Tailored Treatment Plans Show Similar Results for Rheumatoid Arthritis
This randomized controlled trial of 308 adults with DMARD-naīre Rheumatoid Arthritis found no significant difference in mean DAS trajectorie…
A new trial shows that tailoring initial medications based on autoantibody status does not change clinical outcomes for patients with rheuma…
Inaccessible infrastructure and stigma create significant barriers to WASH access for adults with musculoskeletal disabilities
Primary Care & Family Medicine Meta-analysis
Inaccessible infrastructure and stigma create significant barriers to WASH access for adults with musculoskeletal disabilities Identifying Barriers to Water and Sanitation for People with Disabilities
This qualitative systematic review of 19 studies identifies key barriers, facilitators, and interventions regarding water, sanitation, and h…
People with musculoskeletal disabilities face unique barriers like stigma and inaccessible infrastructure when trying to access clean water …
Smoking exposure dominates literature on autoimmune inflammatory rheumatic diseases with limited immune-mechanism integration
Rheumatology Guideline
Smoking exposure dominates literature on autoimmune inflammatory rheumatic diseases with limited immune-mechanism integration Mapping the link between smoking and autoimmune joint diseases
This evidence map of 433 studies identifies a high prevalence of smoking and tobacco research in autoimmune inflammatory rheumatic diseases.…
A large review of research shows that while smoking is heavily studied in arthritis, many studies lack deep data on how it affects immune sy…
Ixekizumab Q2W shows highest P-score among IL-17 inhibitors for active psoriatic arthritis
Allergy & Immunology Meta-analysis
Ixekizumab Q2W shows highest P-score among IL-17 inhibitors for active psoriatic arthritis New data shows IL-17 inhibitors work for psoriatic arthritis
This network meta-analysis of IL-17 pathway inhibitors in adults with active psoriatic arthritis found all active treatments superior to pla…
Several types of IL-17 pathway inhibitors show promise in treating joint pain and skin issues for people with active psoriatic arthritis.
JAK inhibitors maintain efficacy in patients with multiple prior biologic DMARD failures
Rheumatology Meta-analysis
JAK inhibitors maintain efficacy in patients with multiple prior biologic DMARD failures New Options Found for Difficult to Treat Rheumatoid Arthritis
This meta-analysis of 131 studies evaluates treatments for difficult-to-treat rheumatoid arthritis (D2T RA). The analysis found that Janus k…
Patients with difficult to treat rheumatoid arthritis may have more effective options when previous medications fail to control their sympto…
Certolizumab pegol dose escalation from 200 mg to 400 mg results in 2-fold increase in plasma concentration
Rheumatology RCT
Certolizumab pegol dose escalation from 200 mg to 400 mg results in 2-fold increase in plasma concentration Trial shows dose changes impact drug levels in rheumatoid arthritis
This post hoc analysis of a Phase III trial and open-label extension evaluated certolizumab pegol pharmacokinetics in 982 patients with acti…
New analysis shows that changing the dosage of certolizumab pegol directly affects how much medicine stays in a patient's bloodstream.